natgillin/translations-raw huggingface dataset:
Sevelamer carbonate Zentiva should only be given to pregnant women if clearly needed and after a careful risk/benefit analysis has been conducted for both the mother and the foetus.
Zdravilo Sevelamer carbonate Zentiva naj nosečnice uporabljajo le, če ga nujno potrebujejo, in po skrbni presoji razmerja med koristmi in tveganjem za mater in zarodek.
Sevelamer carbonate Zentiva treatment should be re-evaluated in patients who develop severe constipation or other severe gastrointestinal symptoms.
Pri bolnikih, ki imajo hudo zaprtje ali druge hude gastrointestinalne simptome, je treba ponovno pretehtati smiselnost zdravljenja z zdravilom Sevelamer carbonate Zentiva.
Sevelamer contains multiple amines separated by one carbon from the polymer backbone which become protonated in the stomach.
Sevelamer vsebuje številne amine, ki jih od polimerne verige ločuje le en ogljik, ki postanejo v črevesju protonirani.
Sevelamer has no or negligible influence on the ability to drive and use machines.
Sevelamer nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
Sevelamer has no or negligible influence on the ability to drive and use machines.
Sevelamer nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanje s stroji.
Sevelamer hydrochloride should be used within the context of a multiple therapeutic approach, which could include calcium supplements, 1,25-dihydroxy Vitamin D3 or one of its analogues to control the development of renal bone disease.
Sevelamerijev klorid je treba uporabljati v smislu večstranskega pristopa zdravljenja, ki lahko vključuje kalcijeve dodatke, 1,25 – dihidroksi vitamin D3 ali kakšen njegov analog, za nadziranje razvoja renalne osteodistrofije.
Sevelamer hydrochloride, which contains the same active moiety as sevelamer carbonate, has been given to normal healthy volunteers in doses of up to 14 grams per day for eight days with no undesirable effects.
Sevelamerijev klorid, ki vsebuje enako zdravilno učinkovino kot sevelamerijev karbonat, so dajali zdravim prostovoljcem v odmerkih do 14 gramov na dan za osem dni brez pojava neželenih učinkov.
Sevelamer hydrochloride, which contains the same active moiety as sevelamer carbonate, is not absorbed from the gastrointestinal tract, as confirmed by an absorption study in healthy volunteers.
Sevelamerijev klorid, ki vsebuje enako zdravilno učinkovino kot sevelamerijev karbonat, se ne absorbira iz prebavnega trakta, kar potrjuje študija absorpcije pri zdravih prostovoljcih.
Sevelamer: Co-administration of sevelamer (2400 mg tid) did not affect the pharmacokinetics of cinacalcet.
Sevelamer: Sočasna uporaba sevelamera (2400 mg trikrat na dan) ni vplivala na farmakokinetiko cinakalceta.
Sevelamer: Co-administration of sevelamer (2400 mg, three times a day) did not affect the pharmacokinetics of cinacalcet.
Sevelamer: Sočasna uporaba sevelamera (2400 mg trikrat na dan) ni vplivala na farmakokinetiko cinakalceta.
Seven days after the Elonva injection, if further ovarian stimulation is needed, injections of another
Če je potrebno dodatno spodbujanje jajčnikov, se lahko sedem dni po injiciranju zdravila Elonva uporabi injekcija drugega zdravila, ki je podobno zdravilu Elonva, vendar je primerno za dnevno injiciranje.
Seven days pre-treatment with rifampicin (600 mg) followed by co- administration of repaglinide (a single dose of 4 mg) at day seven resulted in a 50% lower AUC (effect of a combined induction and inhibition).
Pri sedemdnevnem predzdravljenju z rifampicinom (v odmerku 600 mg) in kasnejšemu dodatku repaglinida (v enkratnem odmerku 4 mg) sedmi dan, se je vrednost AUC znižala za 50 % (kombinirani učinek indukcije in inhibicije).
Seven days pre-treatment with rifampicin (600 mg), followed by co- administration of repaglinide (a single dose of 4 mg) at day seven resulted in a 50% lower AUC (effect of a combined induction and inhibition).
Pri sedemdnevnem predzdravljenju z rifampicinom (v odmerku 600 mg) in kasnejšemu dodatku repaglinida (v enkratnem odmerku 4 mg) sedmi dan, se je vrednost AUC znižala za 50 % (kombinirani učinek indukcije in inhibicije).
Seven major metabolites, including hydroxyl, demethyl, and hydroxydemethyl, are identifiable in whole blood.
V krvi so našli sedem pomembnejših metabolitov, med njimi hidroksilno, demetilno in hidroksidemetilno obliko.
Seven of 11 (64%) subjects in Group 1 (ca A/Vietnam/1204/2004 [H5N1]) had ≥ 4-fold rises in HAI antibody titer by Day 7 following receipt of the inactivated vaccine, with a geometric mean titer (GMT) of 165 and a titer range of 20 to 1280 in responders.
Sedem od 11 (64 %) preiskovancev v 1. skupini (ca A/Vietnam/1204/2004 [H5N1]) je do 7. dne po prejemu inaktiviranega cepiva imelo ≥ 4-kraten porast titra protiteles HAI; pri tistih, ki so se odzvali, je bila geometrična sredina titrov 165, razpon titrov pa od 20 do 1280.
Seven patients (1.6%) developed positive anti-tocilizumab antibodies; of these, six (1.4%) developed neutralizing anti-tocilizumab antibodies.
Pri sedmih bolnikih (1,6 %) so se pojavila protitelesa proti tocilizumabu, od teh pri šestih (1,4 %) nevtralizacijska.
Seven patients had measurable values (from 0.105 to
Sedem bolnikov je imelo merljive vrednosti (od 0,105 do
Seventeen (17) patients treated with ZALTRAP (1.6 %) and two (2) placebo-treated patients (0.2%) were also positive in the neutralising antibody assay.
Sedemnajst (17) prejemnikov zdravila ZALTRAP (1,6 %) in dva (2) prejemnika placeba (0,2 %) so imeli tudi pozitiven preskus na nevtralizirajoča protitelesa.
Seventeen (4.5%) patients on sunitinib versus 5 (1.7%) of patients on IFN-α experienced Grade 3 or greater bleeding events.
Krvavitve 3. ali višje stopnje so se pojavile pri 17 (4,5 %) bolnikih, ki so prejemali sunitinib, in pri 5 bolnikih (1,7 %), ki so prejemali IFN-α.
Seventeen percent of samples from the exterior of occlusive dressing tested positive for talimogene laherparepvec DNA but none tested positive for presence of infective virus.
Sedemnajst odstotkov vzorcev iz zunanjosti okluzivnega povoja je bilo pozitivnih za DNA talimogena laherparepveka, vendar ni bil noben pozitiven za prisotnost infektivnega virusa.
Seventy percent (70%) (162/230) of genotype 1a subjects no longer had any RAVs detected at the boceprevir-resistance associated loci by population sequencing.
Pri sedemdesetih odstotkih (70 %) (162/230) preiskovancev, okuženih z genotipom 1a, s populacijskim sekveniranjem niso več zaznali nobenih RAV na lokusih, povezanih z odpornostjo na boceprevir.
Seventy-five percent (21/28) of immune-active patients in the tenofovir disoproxil fumarate group had normal ALT at week 72 compared to 34% (11/32) in the placebo group.
Petinsedemdeset odstotkov (21/28) imunsko aktivnih bolnikov v skupini, ki je prejemala dizoproksiltenofovirijev fumarat, je imelo v 72. tednu normalne koncentracije ALT v primerjavi s 34% (11/32) v skupini, ki je prejemala placebo.
Seventy-four percent (26/35) of patients in the tenofovir disoproxil fumarate group had normalised ALT at week 72 compared to 31% (13/42) in the placebo group.
Štiriinsedemdeset odstotkov (26/35) bolnikov v skupini, ki je prejemala dizoproksiltenofovirijev fumarat, je imelo v 72. tednu normalizirani ALT v primerjavi z 31% (13/42) v skupini, ki je prejemala placebo.
Seventy-four percent of patients had received prior ASCT.
Štiriinsedemdesetim odstotkom bolnikov so predhodno opravili avtologno presaditev matičnih celic.
Seventy-nine (20.1%) patients were treated concomitantly with disease modifying anti − rheumatic drugs, and 37 (9.4%) patients with glucocorticoids.
Devetinsedemdeset (20,1%) bolnikov je sočasno dobivalo imunomodulacijska antirevmatična zdravila, 37 (9,4%) bolnikov pa glukokortikoide.
Seventy-nine (20.1%) patients were treated concomitantly with disease modifying anti-rheumatic drugs, and 37 (9.4%) patients with glucocorticoids.
Devetinsedemdeset (20,1 %) bolnikov je sočasno dobivalo imunomodulacijska antirevmatična zdravila, 37 (9,4 %) bolnikov pa glukokortikoide.
Seventy-nine percent were male, 63% were White, 18% were Black, and 14% were Asian.
Devetinsedemdeset odstotkov je bilo moških, 63 % je bilo belcev, 18 % je bilo črncevin 14 % je bilo Azijcev.
Seventy-one cases (in 55 patients) of bradycardia (two of which were assessed as serious, the remainder as non-serious) were reported in clinical trials.
V kliničnih preskušanjih so zabeležili 71 primerov bradikardije (pri 55 bolnikih); dva od teh primerov so ocenili kot resna, preostali niso bili resni.
Seventy-one patients were randomised to receive bolus 5-FU/FA or 5-FU/FA  Avastin (5 mg/kg every 2 weeks).
Randomiziranih je bilo 71 bolnikov, ki so prejeli bolus 5-FU/FA ali 5-FU/FA  Avastin (5 mg/kg vsaka dva tedna).
Seventy-one percent (71%) of patients had baseline tophi.
Ob izhodišču je imelo 71 % bolnikov tofe.
Seventy-seven of 106 patients (73%) continued crizotinib treatment for at least 3 weeks after objective disease progression.
106 (73 %) bolnikov je po objektivnem napredovanju bolezni vsaj 3 tedne nadaljevalo zdravljenje s krizotinibom.
Seventy-three percent (73%) of patients enrolled into the ACTIVE-A study were unable to take VKA due to physician assessment, inability to comply with INR (international normalised ratio) monitoring, predisposition to falling or head trauma, or specific risk of bleeding; for 26% of the patients, the physician’s decision was based on the patient’s unwillingness to take VKA.
Triinsedemdeset odstotkov (73 %) bolnikov, vključenih v študijo ACTIVE-A, je bilo neprimernih za prejemanje VKA po zdravnikovi oceni, nezmožnosti upoštevanja kontrol INR (internacionalnega normaliziranega razmerja), nagnjenosti k padcem ali poškodbe glave, ali specifičnega tveganja krvavitev; pri 26 % bolnikov je zdravnikova odločitev temeljila na tem, da bolnik ni želel jemati VKA.
Seventy-three percent of non-splenectomised patients receiving romiplostim were able to reduce the dose by more than 25% or discontinue concurrent ITP medical therapies by the end of the study compared to 50% of placebo treated patients (see section 4.5).
Triinsedemdeset odstotkov nesplenektomiranih bolnikov, ki so prejemali romiplostim, je lahko do konca študije zmanjšalo odmerek sočasnih zdravil za ITP za več kot 25% ali je lahko ta zdravila celo opustilo; med bolniki, ki so prejemali placebo, je bilo takšnih 50% (glejte poglavje 4.5).
Several adverse events were solicited in the clinical studies and are designated with the symbol (‡).
Posamezni neželeni dogodki, o katerih v kliničnih študijah niso poročali spontano, so označeni s simbolom(‡).
Several cases of benign colonic polyps occurred during the course of the trials, however, the frequency was not increased compared to placebo-treated patients.
V preskušanjih so zabeležili več primerov benignih polipov kolona, vendar njihova pogostnost ni bila povečana v primerjavi z bolniki na placebu.
Several cases of dexmedetomidine overdose have been reported both in the clinical trial and the post- marketing data.
Poročali so o več primerih prevelikega odmerjanja deksmedetomidina, tako v kliničnih preskušanjih kot v okviru postmarketinških izkušenj.
Several cases of diarrhoea were reported with a compatible timeline.
Poročali so o več primerih dieareje, kjer je časovni interval med začetkom jemanja in nastopom diareje kazal moţno vzročno povezanost.
Several conjugated metabolites were identified, the major ones (inactive) being a glycine conjugate of the acid metabolite of O-dealkylated desaturated pitolisant and a glucuronide of a ketone metabolite of monohydroxy desaturated pitolisant.
Opazili so več konjugiranih presnovkov, med katerimi sta glavna (neaktivna) glicinski konjugat kislinskega presnovka O-dealkiliranega desaturiranega pitolizanta in glukuronid ketonskega presnovka monohidroksi desaturiranega pitolizanta.
Several genotypes of hepatitis C virus exist, and the combination of medicines used and the duration of treatment will depend on the genotype of hepatitis C virus the patient is infected with and the nature of the liver problems they have, for example if they have liver cirrhosis (scarring) or their liver is not working properly.
Obstaja več genotipov virusa hepatitisa C. Uporabljena kombinacija zdravil in trajanje zdravljenja sta odvisna od genotipa virusa hepatitisa C, s katerim je okužen bolnik, in vrste njegovih težav z jetri (ali gre na primer za cirozo (brazgotinjenje) jeter ali njihovo nepravilno delovanje).
Several genotypes of hepatitis C virus exist, and the combination of medicines used and the duration of treatment will depend on which genotype of hepatitis C virus the patient is infected with, and the nature of the liver problems they have (for example, if they have liver cirrhosis (scarring) or their liver is not working properly).
Obstaja več genotipov virusa hepatitisa C. Uporabljena kombinacija zdravil in trajanje zdravljenja sta odvisna od genotipa virusa hepatitisa C, s katerim je okužen bolnik, in vrste njegovih težav z jetri (ali
Several metabolites have been detected, but only three of them have been identified:
Zaznali so več presnovkov, od katerih so identificirali le tri: 6 alfa-hidroksipaklitaksel,
Several of the interaction studies (indicated by # in the table below) have been performed at lower than recommended doses of darunavir or with a different dosing regimen (see section 4.2 Posology).
Številne interakcijske študije (označene z # v spodnji preglednici) so bile izvedene pri odmerkih darunavirja, ki so bili nižji od priporočenega ali z različnimi režimi odmerjanja (glejte poglavje 4.2 Odmerjanje).
Several of the interaction studies (indicated by # in the table below) have been performed at lower than recommended doses of darunavir or with a different dosing regimen (see section 4.2 Posology).
Številne študije medsebojnega delovanja z drugimi zdravili (označene z # v spodnji preglednici) so bile opravljene pri odmerkih darunavirja, ki so bili nižji od priporočenega ali z drugačnimi režimi odmerjanja (glejte poglavje 4.2 Odmerjanje).
Several of the interaction studies (indicated by # in the table below) have been performed at lower than recommended doses of darunavir or with a different dosing regimen (see section 4.2 Posology).
Številne študije medsebojnega delovanja z drugimi zdravili (označene z # v spodnji preglednici) so bile opravljene pri odmerkih darunavirja, ki so bili nižji od priporočenega ali z drugačnimi režimi odmerjanja (glejte poglavje 4.2 Odmerjanje.
Several of the interaction studies have been performed with darunavir at lower than recommended doses.
Izvedenih je bilo več študij medsebojnega delovanja z drugimi zdravili pri odmerkih darunavirja, ki so bili nižji od priporočenega.
Several other side effects are seen in more than 1 patient in 10.
Pojavili so se še nekateri drugi neželeni učinki, ki so bili opaženi pri več kot 1 bolniku od 10.
Several patients showed an increase in height (n=7) and weight (n=3) for age Z-score.
Pri več bolnikih smo opazili povečano višino (n=7) in težo (n=3) za starost Z- štetja.
Several published studies have established the usefulness of lutetium (177Lu) in radiolabelling medicines for diagnosing and treating neuroendocrine tumours.
Več objavljenih študij je potrdilo uporabnost lutecija (177Lu) pri radioaktivnem označevanju zdravil za diagnostične namene in zdravljenje nevroendokrinih tumorjev.
Several published studies have established the usefulness of lutetium (177Lu) in radiolabelling medicines for diagnosing and treating neuroendocrine tumours.
Več objavljenih študij je potrdilo uporabnost lutecija (177Lu) pri radiooznačevanju zdravil za diagnostične namene in zdravljenje nevroendokrinih tumorjev.
Several studies show that Olysio in combination with peginterferon alfa and ribavirin or with sofosbuvir is effective in clearing the hepatitis C virus from the blood after 12 or 24 weeks of treatment.
Več raziskav potrjuje, da zdravilo Olysio v kombinaciji s peginterferonom alfa in ribavirinom ali sofosbuvirjem po 12 ali 24 tednih zdravljenja učinkovito odstranjuje virus hapatitisa C iz krvi.
Several varieties (genotypes) of hepatitis C virus exist, and the duration of treatment with Sovaldi will depend on the genotype of the virus and on which medicines are used together with Sovaldi.
Ker obstaja več vrst (genotipov) virusa hepatitisa C, je trajanje zdravljenja z zdravilom Sovaldi odvisno od genotipa virusa in od tega, katera zdravila se uporabljajo v kombinaciji z njim.
Several varieties (genotypes) of hepatitis C virus exist: Olysio has been shown to be effective against genotypes 1 and 4.
Obstaja več vrst (genotipov) virusa hepatitisa C: zdravilo Olysio se je izkazalo za učinkovito proti genotipoma 1 in 4.
Severe
huda
Severe
Huda okvara
Severe
Hude
Severe
Resne
Severe
Resni
Severe
težka
Severe (< 30) (n = 6)
huda okvara (<30) (n = 6)
Severe (grade 3 or 4) fatigue and asthenia incidence was 3 and 3 % respectively.
Incidenca hude utrujenosti in astenije (3. ali 4. stopnje) je bila 3 % pri obeh.
Severe (grade 3) or intolerable nausea, vomiting or diarrhoea despite optimal anti-emetic or anti-diarrhoeal therapy
zelo izraženi (stopnje 3) ali neznosni naslednji simptomi: navzea, bruhanje ali diareja, kljub optimalnemu antiemetičnemu oziroma antidiaroičnemu zdravljenju
Severe (Grade 3/4) hypersensitivity reactions including anaphylaxis occur in less than 1% of patients (see also section ‘Special warnings and precautions for use’).
Hude preobčutljivostne reakcije (3./4. stopnje) vključno z anafilaksijo so se pojavile pri manj kot 1 % bolnikov (glejte tudi poglavje Posebna opozorila in previdnostni ukrepi).
Severe (grade 3/4) neutropenia was reported in 4.2%, anaemia in 1.1% and thrombocytopenia in 1.7 % of the patients.
Huda nevtropenija (3. ali 4. stopnje) se je pojavila pri 4,2 % bolnikov, anemija pri 1,1 % in trombocitopenija pri 1,7 % bolnikov.
Severe (NCI-CTC grade 3) skin reactions were reported in 34% and life-threatening (NCI- CTC grade 4) skin reactions in < 1% of patients who received Vectibix in combination with chemotherapy (n = 1536) (see section 4.8).
Poročali so o hudih kožnih reakcijah (3. stopnja po NCI-CTC) pri 34 % bolnikov in o življenjsko ogrožujočih kožnih reakcijah (4. stopnja po NCI-CTC) pri < 1 % bolnikov, ki so prejemali zdravilo Vectibix v kombinaciji s kemoterapijo (n = 1.536) (glejte poglavje 4.8).
Severe (NCI-CTC grade 3) skin reactions were reported in 34% and life-threatening (NCI-CTC grade 4) skin reactions in < 1% of patients who received Vectibix in combination with chemotherapy (n = 1,536).
Poročali so o hudih kožnih reakcijah (3. stopnja po NCI-CTC) pri 34 % bolnikov in o življenjsko ogrožujočih kožnih reakcijah (4. stopnja po NCI-CTC) pri < 1 % bolnikov, ki so prejemali zdravilo Vectibix v kombinaciji s kemoterapijo (n = 1.536).
Severe abdominal pain, blood in your vomit, stools or urine, black stools (signs of gastrointestinal disorders).
hude bolečine v trebuhu, kri v izbruhku, blatu ali urinu, črno blato (znaki bolezni prebavil),
Severe active infections, active chronic infections (hepatitis, tuberculosis).
Aktivne hude okužbe, aktivne kronične okužbe (hepatitis, tuberkuloza).
Severe acute (less than 24 hours) hypersensitivity reactions have been observed both on initial exposure to Simulect and on re-exposure to a subsequent course of therapy.
Hude akutne preobčutljivostne reakcije (v manj kot 24 urah) so opažali tako pri prvi izpostavljenosti Simulectu kot pri ponovni izpostavljenosti ob kasnejši ponovitvi zdravljenja.
Severe acute exacerbations of hepatitis B have been reported in patients who have discontinued anti- hepatitis B therapy including telbivudine (see section 4.4).
Poročali so o hudih akutnih poslabšanjih hepatitisa B pri bolnikih, ki so prekinili zdravljenje hepatitisa B (vključno z zdravljenjem s telbivudinom) (glejte poglavje 4.4).
Severe allergic (anaphylactic) reactions (rare; may affect up to 1 in 1,000 people), with signs such as: swelling of the face, lips, tongue or throat, difficulty breathing, low blood pressure, dizziness and itchy rash.
Hude alergijske (anafilaktične) reakcije (redko; pojavijo se lahko pri največ 1 od 1.000 bolnikov) z znaki, kot so npr.: otekanje obraza, ustnic, jezika ali žrela, oteženo dihanje, nizek krvni tlak, omotičnost ali srbeč izpuščaj.
Severe allergic (anaphylactic) reactions causing swelling of the lips, face or neck leading to severe difficulty in breathing, skin rash or hives, anaphylactic shock (a severe reduction in blood pressure, paleness, agitation, weak pulse, decreased consciousness).
Hude alergijske (anafilaktične) reakcije, ki povzročijo otekanje ustnic, obraza ali vratu, kar vodi v hude težave z dihanjem, izpuščaj ali koprivnica, anafilaktični šok (močan padec krvnega tlaka, bledica, nemir, pospešen srčni utrip, zožanje zavesti).
Severe allergic or anaphylactic reactions
hude alergijske ali anafilaktične reakcije,
Severe allergic or anaphylactic reactions
hude alergijske ali anafilaktične reakcije;
Severe allergic or anaphylactic reactions
hude alergijske reakcije ali anafilaktične reakcije;
Severe allergic reaction
resne alergijske reakcije
Severe allergic reaction (anaphylactic reaction) signs of which may include difficulty breathing, chest pain or chest tightness, and/or feeling dizzy/faint, severe itching of the skin or raised lumps on the skin, swelling of the face, lips, tongue and /or throat, which may cause difficulty in swallowing, collapse
znaki hude alergijske reakcije (anafilaktična reakcija), ki lahko vključujejo oteženo dihanje, bolečino ali tiščanje v prsih in/ali omotico/omedlevico, hudo srbenje kože ali dvignjene bulice na koži, otekanje obraza, ustnic, jezika in/ali grla, kar lahko povzroči oteženo požiranje, kolaps
Severe allergic reaction (anaphylactic reaction) signs of which may include difficulty breathing, chest pain or chest tightness, and/or feeling dizzy/faint, severe itching of the skin or raised lumps on the skin, swelling of the face, lips, tongue and /or throat, which may cause difficulty in swallowing, collapse
znaki hude alergijske reakcije (anafilaktična reakcija), ki lahko vključujejo oteženo dihanje, bolečino ali tiščanje v prsih, in/ali omotico/omedlevico, hudo srbenje kože ali dvignjene bulice na koži, otekanje obraza, ustnic, jezika in/ali grla, kar lahko povzroči oteženo požiranje, kolaps
Severe allergic reaction (anaphylactic reaction), allergic reactions (hypersensitivity) and angioedema (the symptoms of which can include difficulties in breathing or swallowing, rash, itching, hives or swelling of the face, hands and feet, eyes, lips and/or tongue, dizziness)
huda alergijska reakcija (anafilaktična reakcija), alergijske reakcije (preobčutljivost) in angioedem (med njegovimi simptomi so lahko oteženo dihanje ali požiranje, izpuščaj, srbenje, koprivnica ali otekanje v obraz, roke in stopala, oči, ustnice in/ali jezik, omotica),
Severe allergic reaction including shock (cardiovascular collapse); angioedema (swelling of lips, face or throat)
huda alergijska reakcija, vključno s šokom (kardiovaskularni kolaps); angioedem (otekanje ustnic, obraza ali žrela)
Severe allergic reaction that may include difficulty in breathing, facial swelling, localised swelling, and swelling of the limbs.
huda alergijska reakcija, ki lahko vključuje oteženo dihanje, otekanje obraza, lokalizirano otekanje in otekanje okončin
Severe allergic reaction to the active substance or to any of the excipients listed in section 6.1.
Huda alergijska reakcija na zdravilno učinkovino ali katero koli pomožno snov, navedeno v poglavju 6.1.
Severe allergic reaction with low blood pressure (shock)
Huda alergijska reakcija z nizkim krvnim takom (šok)
Severe allergic reaction with low blood pressure (shock)
Huda alergijska reakcija z nizkim krvnim tlakom (šok)
Severe allergic reaction with low blood pressure (shock)
Huda alergijska reakcija z nizkim tlakom (šok)
Severe allergic reaction with shock;
huda alergijska reakcija s šokom;
Severe allergic reaction.
hude alergijske reakcije,
Severe allergic reaction: shortness of breath, swelling mainly of the face and throat.
Huda alergijska reakcija: kratka sapa, oteklost predvsem obraza in žrela.